Overview

A Window of Opportunity Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical Cystectomy

Status:
Not yet recruiting

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn about the safety and efficacy of giving pembrolizumab before a cystectomy (a surgery to remove the bladder) to patients with urothelial carcinoma of the bladder. This is an investigational study. Pembrolizumab is FDA approved and commercially available to treat many types of cancer, but not bladder cancer. It is considered investigational to use pembrolizumab to treat bladder cancer. The study doctor can explain how the study drug is designed to work. Up to 20 participants will be enrolled in this study. All will take part at MD Anderson.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab